JP2010509575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509575A5 JP2010509575A5 JP2009535557A JP2009535557A JP2010509575A5 JP 2010509575 A5 JP2010509575 A5 JP 2010509575A5 JP 2009535557 A JP2009535557 A JP 2009535557A JP 2009535557 A JP2009535557 A JP 2009535557A JP 2010509575 A5 JP2010509575 A5 JP 2010509575A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- diabetes
- pro
- sequelae
- risk stratification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003550 marker Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 238000013517 stratification Methods 0.000 claims 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 108010012004 proadrenomedullin Proteins 0.000 claims 3
- 102000034567 proadrenomedullin Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108010074051 C-Reactive Protein Proteins 0.000 claims 2
- 102100032752 C-reactive protein Human genes 0.000 claims 2
- 102100034296 Natriuretic peptides A Human genes 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102400000345 Angiotensin-2 Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 101800000285 Big gastrin Proteins 0.000 claims 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 1
- 102000004420 Creatine Kinase Human genes 0.000 claims 1
- 108010042126 Creatine kinase Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 102400000686 Endothelin-1 Human genes 0.000 claims 1
- 101800004490 Endothelin-1 Proteins 0.000 claims 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 102400000569 Myeloperoxidase Human genes 0.000 claims 1
- 108090000235 Myeloperoxidases Proteins 0.000 claims 1
- 102100030856 Myoglobin Human genes 0.000 claims 1
- 108010062374 Myoglobin Proteins 0.000 claims 1
- -1 NT-proANP Proteins 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- 101710187800 Natriuretic peptides A Proteins 0.000 claims 1
- 102100036836 Natriuretic peptides B Human genes 0.000 claims 1
- 101710187802 Natriuretic peptides B Proteins 0.000 claims 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 claims 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 claims 1
- 102100028427 Pro-neuropeptide Y Human genes 0.000 claims 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 1
- 108010048233 Procalcitonin Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000003748 differential diagnosis Methods 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 230000001452 natriuretic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 1
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 claims 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims 1
- 108010072272 proendothelin 1 Proteins 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 108010088603 proneuropeptide Y Proteins 0.000 claims 1
- 108010001670 prosomatostatin Proteins 0.000 claims 1
- GGYTXJNZMFRSLX-UHFFFAOYSA-N prosomatostatin Chemical compound C1CCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NCC(=O)NC2C(NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C4=CC=CC=C4NC=3)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(C(=O)NC(CO)C(=O)NC(CSSC2)C(O)=O)C(C)O)C(C)O)=O)N1C(=O)C(C)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C1CCCN1C(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(N)CO GGYTXJNZMFRSLX-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006052916A DE102006052916A1 (de) | 2006-11-08 | 2006-11-08 | Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM |
| DE102006052916.2 | 2006-11-08 | ||
| PCT/DE2007/002018 WO2008055491A2 (de) | 2006-11-08 | 2007-11-08 | Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235494A Division JP2013047689A (ja) | 2006-11-08 | 2012-10-25 | ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509575A JP2010509575A (ja) | 2010-03-25 |
| JP2010509575A5 true JP2010509575A5 (enExample) | 2010-11-25 |
| JP5275247B2 JP5275247B2 (ja) | 2013-08-28 |
Family
ID=39277540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535557A Active JP5275247B2 (ja) | 2006-11-08 | 2007-11-08 | ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出 |
| JP2012235494A Pending JP2013047689A (ja) | 2006-11-08 | 2012-10-25 | ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235494A Pending JP2013047689A (ja) | 2006-11-08 | 2012-10-25 | ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20100035275A1 (enExample) |
| EP (1) | EP2097748B1 (enExample) |
| JP (2) | JP5275247B2 (enExample) |
| CN (2) | CN101568833B (enExample) |
| DE (1) | DE102006052916A1 (enExample) |
| ES (1) | ES2393262T3 (enExample) |
| WO (1) | WO2008055491A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| EP2016394A4 (en) | 2006-04-04 | 2013-04-24 | Singulex Inc | METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| ES2795003T3 (es) * | 2008-10-07 | 2020-11-20 | Brahms Gmbh | Biomarcador para la predicción de los primeros eventos adversos |
| EP2180322A1 (en) * | 2008-10-22 | 2010-04-28 | BRAHMS Aktiengesellschaft | Prognostic biomarkers for the progression of primary chronic kidney disease |
| US20110262939A1 (en) * | 2008-10-31 | 2011-10-27 | B.R.A.H.M.S Gmbh | Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system |
| CN102203608B (zh) * | 2008-10-31 | 2016-11-23 | B.R.A.H.M.S有限公司 | 用于与代谢综合征、心血管疾病和/或胰岛素抗性相关的病症的诊断、预后、监测和治疗追踪的体外方法 |
| JP5584695B2 (ja) * | 2008-11-11 | 2014-09-03 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| CN102472752B (zh) * | 2009-08-28 | 2015-08-19 | B.R.A.H.M.S有限公司 | 用于不良事件的预后的降钙素原 |
| RU2017110678A (ru) * | 2010-11-01 | 2019-01-24 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
| AU2012219582A1 (en) * | 2011-02-21 | 2013-08-22 | Fibrostatin S.L. | Methods for treating and diagnosing disease |
| EP2533052A1 (en) * | 2011-06-07 | 2012-12-12 | B.R.A.H.M.S GmbH | Diagnostic use of proSomatostatin |
| CN104714020B (zh) * | 2013-12-12 | 2016-05-25 | 张曼 | 尿液内源性α胰蛋白酶抑制剂重链H4在2型糖尿病合并冠心病中的应用 |
| CN119199150A (zh) * | 2015-11-27 | 2024-12-27 | B.R.A.H.M.S 有限公司 | 作为对象的细胞外容量状态的标志物的MR-proADM |
| RU2765212C2 (ru) * | 2016-08-09 | 2022-01-26 | Б.Р.А.Х.М.С. Гмбх | Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии |
| JP7194673B2 (ja) * | 2016-08-09 | 2022-12-22 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 臓器障害を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ |
| EP3438668A1 (en) * | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
| EP3682247B1 (en) * | 2017-09-13 | 2022-02-09 | B.R.A.H.M.S GmbH | Proadrenomedullin as a marker for abnormal platelet levels |
| US11892456B2 (en) * | 2017-11-17 | 2024-02-06 | Tokai University Educational System | Method of examining diabetic complication |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69602756T2 (de) * | 1995-08-18 | 2000-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
| DE19847690A1 (de) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| US6756783B2 (en) * | 1999-06-01 | 2004-06-29 | Merlin Technology, Inc | Multi-frequency boring tool locating system and method |
| ES2254220T3 (es) * | 1999-09-10 | 2006-06-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Determinacion de proteinas de enlace con la adrnomedulina. |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| WO2004097423A1 (en) * | 2003-04-25 | 2004-11-11 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| ES2300681T3 (es) * | 2004-07-22 | 2008-06-16 | Brahms Aktiengesellschaft | Procedimiento para el diagnostico y tratamiento de pacientes criticos con endotelina, agonistas de endotelina y antagonistas de adrenomedulina. |
| GB2418995B (en) * | 2004-09-29 | 2006-08-16 | Bookham Technology Plc | Apodised binary grating |
| FI20050011L (fi) * | 2005-01-05 | 2006-07-06 | Jurilab Ltd Oy | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi |
-
2006
- 2006-11-08 DE DE102006052916A patent/DE102006052916A1/de not_active Withdrawn
-
2007
- 2007-11-08 EP EP07866202A patent/EP2097748B1/de active Active
- 2007-11-08 CN CN200780041709.4A patent/CN101568833B/zh active Active
- 2007-11-08 US US12/514,194 patent/US20100035275A1/en not_active Abandoned
- 2007-11-08 ES ES07866202T patent/ES2393262T3/es active Active
- 2007-11-08 JP JP2009535557A patent/JP5275247B2/ja active Active
- 2007-11-08 CN CN201410442798.5A patent/CN104198735B/zh active Active
- 2007-11-08 WO PCT/DE2007/002018 patent/WO2008055491A2/de not_active Ceased
-
2012
- 2012-10-25 JP JP2012235494A patent/JP2013047689A/ja active Pending
-
2016
- 2016-02-26 US US15/055,406 patent/US20160169912A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509575A5 (enExample) | ||
| JP5275247B2 (ja) | ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出 | |
| JP5584473B2 (ja) | Ｎｙｈａｉ患者についての心機能不全の診断および危険性層化のためのナトリウム利尿ペプチドのインビトロ決定 | |
| JP5584695B2 (ja) | Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 | |
| DK2823314T3 (en) | Predicting outcome in patients with chronic obstructive pulmonary disease | |
| JP5320294B2 (ja) | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 | |
| JP2010507786A5 (enExample) | ||
| US8647830B2 (en) | Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease | |
| JP5190067B2 (ja) | Ｎｔ−プロｂｎｐと組み合わせてのｃｔ−プロｅｔ−１による急性冠症候群の診断および危険性の分類 | |
| JP2010513880A5 (enExample) | ||
| EP1970709B1 (en) | The use of BNP-type peptides for predicting the need for dialysis | |
| Lu et al. | Establishment of reference intervals for soluble ST2 from a United States population | |
| CN102203621A (zh) | 用于初次慢性肾脏疾病的发展的预后生物标志物 | |
| JP2012507020A5 (enExample) | ||
| EP2836841A1 (en) | Prognosis of adverse events in patients with suspected chronic heart failure | |
| WO2010125165A1 (en) | Means and methods for diagnosing a heart failure associated kidney damage in individuals in need of a suitable therapy | |
| JP2015537208A (ja) | 心不全リスクの予測改善のためのバイオマーカー | |
| JP2010511877A5 (enExample) | ||
| Banaszak et al. | Endothelin-1 (ET-1), N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP), and tumour necrosis factor alpha (TNF-α) in children with primary hypertension and hypertension of renal origin | |
| ATE412910T1 (de) | Verwendung von herzhormonen zur diagnose des kardiovaskuläre risikos als folge einer verabreichung von entzündungshemmern | |
| JP2008076394A (ja) | ナトリウム利尿ペプチド、および胎盤増殖因子（ＰｌＧＦ）／可溶性ＶＥＧＦ受容体が妊婦における心疾患に関連した心機能不全と胎盤関連心機能不全とを区別する | |
| EP2064555A1 (en) | Natriuretic peptides for diagnosing cardiac complications due to coronary catheterization | |
| JP2012516436A5 (enExample) | ||
| HK1137805B (en) | Diagnosis and risk assessment of pancreatic diabetes using mr-proadm |